XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial

We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and clinical activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients with advanced colorectal cancer (CRC). We hypothesized that this regimen would modulate soluble and cellular immune med...

Full description

Saved in:

Bibliographic Details
Main Authors:	Maggie J. Phillips, Olatunji B. Alese, Natalie K. Horvat, Emily Greene, Olumide B. Gbolahan, Kathleen Coleman, Deon B. Doxie, Vaunita Parihar, Zaid K. Mahdi, Ashley McCook-Veal, Jeffrey M. Switchenko, Maria Diab, Cameron J. Herting, Chrystal M. Paulos, Bassel F. El-Rayes, Gregory B. Lesinski
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	OncoImmunology
Subjects:	Clinical trial colorectal cancer cytokines heat shock protein immune checkpoint inhibitors immunotherapy
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2475620
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial

Similar Items